Details for Patent: 8,383,150

Which drugs does patent 8,383,150 protect, and when does it expire?

Patent 8,383,150 protects ESBRIET and is included in two NDAs.

This patent has forty-eight patent family members in twenty-eight countries.

Summary for Patent: 8,383,150

Title:	Granulate formulation of pirfenidone and pharmaceutically acceptable excipients
Abstract:	A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.
Inventor(s):	Radhakrishnan; Ramachandran (Fremont, CA), Vladyka; Ronald (Somerset, NJ), Sultzbaugh; Kenneth (Bridge Water, NJ)
Assignee:	Intermune, Inc. (Brisbane, CA)
Application Number:	13/162,048
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,383,150
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 8,383,150

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genentech Inc	ESBRIET	pirfenidone	CAPSULE;ORAL	022535-001	Oct 15, 2014	AB	RX	Yes	Yes			Y			METHOD OF ADMINISTERING A GRANULATE FORMULATION OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AS RECITED IN CLAIM 1, TO TREAT IDIOPATHIC PULMONARY FIBROSIS
Genentech Inc	ESBRIET	pirfenidone	TABLET;ORAL	208780-001	Jan 11, 2017	AB	RX	Yes	No			Y			METHOD OF ADMINISTERING A GRANULATE FORMULATION OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AS RECITED IN CLAIM 1, TO TREAT IDIOPATHIC PULMONARY FIBROSIS
Genentech Inc	ESBRIET	pirfenidone	TABLET;ORAL	208780-002	Jan 11, 2017		DISCN	Yes	No			Y			METHOD OF ADMINISTERING A GRANULATE FORMULATION OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AS RECITED IN CLAIM 1, TO TREAT IDIOPATHIC PULMONARY FIBROSIS
Genentech Inc	ESBRIET	pirfenidone	TABLET;ORAL	208780-003	Jan 11, 2017	AB	RX	Yes	Yes			Y			METHOD OF ADMINISTERING A GRANULATE FORMULATION OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AS RECITED IN CLAIM 1, TO TREAT IDIOPATHIC PULMONARY FIBROSIS

International Family Members for US Patent 8,383,150

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	2655
Australia	2006295440
Australia	2011201520
Australia	2013201986